Form 4: AbbVie Director Alpern Boosts Stake with Stock Units

AbbVie Director Robert J. Alpern acquired 33 stock equivalent units at $231.54 each on September 30, 2025, bringing his total beneficial ownership to 10,151 units.

Summary

• Robert J. Alpern, a Director of AbbVie Inc. (ABBV), acquired 33 stock equivalent units.
• The transaction occurred on September 30, 2025, with each unit valued at $231.54.
• These units represent director fees credited to grantor trusts and earn the same return as if invested in AbbVie common stock.
• The units will be paid in cash, generally at age 65 or upon retirement from AbbVie's board.
• Following this transaction, Alpern beneficially owns 10,151 stock equivalent units, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The filing reports a routine director compensation transaction, which is generally neutral. The acquisition of units, even if through compensation, can be seen as a minor positive as it increases director alignment with shareholder interests.

Positives

• Director Robert J. Alpern increased his beneficial ownership in AbbVie by acquiring 33 stock equivalent units.
• The balance of stock equivalent units includes those acquired through a dividend reinvestment feature, indicating ongoing participation in company performance.

Future Outlook

The stock equivalent units will be paid in cash, generally at age 65 or upon retirement from AbbVie's board, indicating a long-term compensation structure.

Industry Context

The use of stock equivalent units as a form of director compensation is a common practice in large, publicly traded companies, including those in the pharmaceutical industry, aligning director interests with shareholder value over the long term.

Comparison to Industry Standards

• This compensation mechanism, where director fees are converted into stock equivalent units that track the company's stock performance and are paid out upon retirement or a specific age, is a standard practice across many large-cap companies.
• Peers in the pharmaceutical sector like Pfizer, Merck, and Johnson & Johnson often utilize similar deferred compensation plans to retain and incentivize their board members.

Related Party Transactions

• The acquisition of 33 stock equivalent units by Director Robert J. Alpern constitutes a related party transaction as it involves compensation from the issuer to a member of its board.

Stakeholder Impact

• Shareholders: Minor positive impact due to increased alignment of a director's financial interests with the company's stock performance through stock equivalent units.

Next Steps

• Payout of stock equivalent units in cash, generally at age 65 or upon retirement from AbbVie's board.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of stock equivalent units by a director as part of their compensation plan. Such transactions are generally not indicative of significant new information regarding the company's operational performance or future prospects and do not warrant a change in investment thesis. The transaction is a standard part of director compensation and does not suggest any immediate catalysts for a 'buy' or 'sell' recommendation.

Keywords

AbbVie, ABBV, Form 4, Insider Transaction, Director Compensation, Stock Equivalent Units, Robert J. Alpern, Equity Compensation, Pharmaceuticals